This paper is in the following e-collection/theme issue:

Systematic Review Protocols (268) Drug Repurposing and Off-Label Use (25)

Published on in Vol 12 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/38658, first published .
The Efficacy, Safety, and Efficiency of the Off-Label Use of Bevacizumab in Patients Diagnosed With Age-Related Macular Degeneration: Protocol for a Systematic Review and Meta-Analysis

The Efficacy, Safety, and Efficiency of the Off-Label Use of Bevacizumab in Patients Diagnosed With Age-Related Macular Degeneration: Protocol for a Systematic Review and Meta-Analysis

The Efficacy, Safety, and Efficiency of the Off-Label Use of Bevacizumab in Patients Diagnosed With Age-Related Macular Degeneration: Protocol for a Systematic Review and Meta-Analysis

Authors of this article:

João Estarreja1 Author Orcid Image ;   Priscila Mendes1 Author Orcid Image ;   Carina Silva1, 2 Author Orcid Image ;   Pedro Camacho1 Author Orcid Image ;   Vanessa Mateus1, 3 Author Orcid Image
Article Authors Cited by (2) Tweetations (2) Metrics

Journals

  1. Santorsola M, Capuozzo M, Nasti G, Sabbatino F, Di Mauro A, Di Mauro G, Vanni G, Maiolino P, Correra M, Granata V, Gualillo O, Berretta M, Ottaiano A. Exploring the Spectrum of VEGF Inhibitors’ Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice. Cancers 2024;16(2):350 View
  2. Estarreja J, Mendes P, Silva C, Camacho P, Mateus V. Off-Label Use of Bevacizumab in Patients Diagnosed with Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. Pharmaceuticals 2024;17(8):1000 View